LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.

被引：0

作者：

Jonasch, Eric

Iliopoulos, Othon

Rathmell, Wendy Kimryn

Narayan, Vivek

Maughan, Benjamin L.

Oudard, Stephane

Else, Tobias

Maranchie, Jodi K.

Welsh, Sarah Joanne

Iversen, Ane Bundsbaek Bondergaard

Roy, Ananya

Liu, Yanfang

Perini, Rodolfo F.

Linehan, W. Marston

Srinivasan, Ramaprasad

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[5] Univ Penn, Philadelphia, PA USA

[6] Univ Utah, Salt Lake City, UT USA

[7] Univ Paris, Georges Pompidou Hosp, Paris, France

[8] Univ Michigan, Ann Arbor, MI USA

[9] Univ Pittsburgh, Pittsburgh, PA USA

[10] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[11] Aarhus Univ Hosp, Aarhus, Denmark

[12] Merck & Co Inc, Kenilworth, NJ USA

[13] Natl Canc Inst, Ctr Canc Res, Bethesda, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4546

引用

页数：1